Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
暂无分享,去创建一个
M. Peyromaure | F. Goldwasser | M. Zerbib | A. Jouinot | M. Allard | N. Khoudour | B. Blanchet | M. Vidal | J. Alexandre | O. Huillard | M. Joulia | E. Carton | Audrey Thomas Schoemann
[1] F. Goldwasser,et al. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. , 2018, Critical reviews in oncology/hematology.
[2] F. Saad,et al. Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.
[3] J. Schellens,et al. Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology , 2018, Clinical Pharmacokinetics.
[4] R. McCool,et al. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] M. Ratain,et al. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] F. Goldwasser,et al. A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[7] H. G. van der Poel,et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.
[8] F. Goldwasser,et al. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. , 2017, European journal of cancer.
[9] C. Kollmannsberger,et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer , 2015, Journal of clinical pharmacology.
[10] T. Ouatas,et al. Pharmacokinetic Drug Interaction Studies with Enzalutamide , 2015, Clinical Pharmacokinetics.
[11] T. Ouatas,et al. Clinical Pharmacokinetic Studies of Enzalutamide , 2015, Clinical Pharmacokinetics.
[12] F. Saad,et al. Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer , 2014, Clinical Pharmacokinetics.
[13] F. Saad,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.
[14] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[15] J. Humm,et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.
[16] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[17] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Kenneth J. Pienta,et al. Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer , 2006, Clinical Cancer Research.
[19] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Tindall,et al. Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.
[21] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.